Antiretroviral APOBEC3 cytidine deaminases alter HIV-1 provirus integration site profiles.
Hannah O AjogeTyler M RennerKasandra BélangerMatthew GreigSamar DankarHinissan P KohioMacon D ColemanEmmanuel NdashimyeEric J ArtsMarc-André LangloisStephen D BarrPublished in: Nature communications (2023)
APOBEC3 (A3) proteins are host-encoded deoxycytidine deaminases that provide an innate immune barrier to retroviral infection, notably against HIV-1. Low levels of deamination are believed to contribute to the genetic evolution of HIV-1, while intense catalytic activity of these proteins can induce catastrophic hypermutation in proviral DNA leading to near-total HIV-1 restriction. So far, little is known about how A3 cytosine deaminases might impact HIV-1 proviral DNA integration sites in human chromosomal DNA. Using a deep sequencing approach, we analyze the influence of catalytic active and inactive APOBEC3F and APOBEC3G on HIV-1 integration site selections. Here we show that DNA editing is detected at the extremities of the long terminal repeat regions of the virus. Both catalytic active and non-catalytic A3 mutants decrease insertions into gene coding sequences and increase integration sites into SINE elements, oncogenes and transcription-silencing non-B DNA features. Our data implicates A3 as a host factor influencing HIV-1 integration site selection and also promotes what appears to be a more latent expression profile.
Keyphrases
- hiv positive
- antiretroviral therapy
- hiv infected
- human immunodeficiency virus
- hiv testing
- hiv aids
- hepatitis c virus
- men who have sex with men
- circulating tumor
- hiv infected patients
- cell free
- south africa
- single molecule
- endothelial cells
- innate immune
- genome wide
- machine learning
- single cell
- circulating tumor cells
- genetic diversity